i
Updated recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients — United States, April 2021
-
April 27, 2021
-
[PDF-137.87 KB]
Details:
-
Personal Author:
-
Corporate Authors:
-
Description:What is already known about this topic? On April 13, 2021, CDC and the Food and Drug Administration (FDA) recommended pausing use of the Janssen COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome (TTS) among vaccine recipients.
What is added by this report? On April 23, the Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed the risks and reaffirmed its interim recommendation under FDA’s Emergency Use Authorization, which includes a new warning for rare clotting events among women aged 18–49 years.
What are the implications for public health practice? Resuming use of the Janssen COVID-19 vaccine will ensure flexibility, choice, and improved access. Education about TTS risk with Janssen COVID-19 vaccine is critical.
Suggested citation for this article: MacNeil JR, Su JR, Broder KR, et al. Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021. MMWR Morb Mortal Wkly Rep. ePub: 27 April 2021.
mm7017e4.htm?s_cid=mm7017e4_w
mm7017e4-H.pdf
-
Subjects:
-
Series:
-
Document Type:
-
Name as Subject:
-
Place as Subject:
-
Location:
-
Pages in Document:6 numbered pages
-
Volume:70
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
